As shown in Fig. 8E-F, both CERS6 and SPTLC2 were markedly upregulated in HCC patients, highlighting their potential as diagnostic and prognostic markers in human MASH-HCC. This evidence concerns the gene CERS6 and hepatocellular carcinoma.